

CURRICULUM VITAE
ROBERT WILLIAM SIMMS, M.D.

Professional Address

Rheumatology Section
Dartmouth Hitchcock Medical Center
One Medical Center Drive
Lebanon, NH 03756

Email: Robert.W.Simms@hitchcock.org; rsimms@bu.edu
Ph: (603) 650-8622; Fax: (603) 650-4691

Home Address

850 Wood Hill Road
Sutton, VT 05867

781-383-0402 (Mobile)

Education

1976 – B.A.	Bucknell University (Magna Cum Laude with Honors in Biology)
1980 – M.D.	University of Rochester School of Medicine

Present Academic Rank and Position

Present-	Professor of Medicine (proposed) Geisel School of Medicine at Dartmouth
	Emeritus Professor of Medicine Boston University School of Medicine

Previous Professional Positions and Appointments

2019 – 2020	Professor of Medicine Boston University School of Medicine
2008 –2019	Section Head, Rheumatology Section Boston University School of Medicine
2005 – 2008	Acting Section Head, Rheumatology Section Boston University School of Medicine

1992 – 2008	Clinical Director, Rheumatology Section Boston University School of Medicine
1994 – 2001	Associate Professor of Medicine, Boston University School of Medicine
1988 – 1994	Assistant Professor of Medicine Boston University School of Medicine
1987 – 1988	Instructor in Medicine Boston University School of Medicine
1982 – 1984	National Health Service Corps, Mattapan, MA

Professional Training

1980 – 1982	Intern and Junior Assistant Resident Department of Medicine, Cornell Cooperating Hospitals North Shore University Hospital – Memorial Hospital, Manhasset, NY
1984 – 1985	Senior Assistant Resident Department of Medicine – Brigham & Women’s Hospital, Boston, MA
1985 – 1987	Clinical and Research Fellow in Rheumatology Boston University School of Medicine, Boston, MA

Professional Affiliations/Honors

1976	Phi Beta Kappa
1976	Phi Sigma (Biology Honor Society)
1983	Massachusetts Medical Society
1986	American College of Rheumatology
1987	New England Rheumatism Society
1991	American Federation of Clinical Research
1991	American College of Physicians
1992	Best Paper, Second International Conference on Myofascial Pain and Fibromyalgia, Copenhagen, Denmark
1992	“Meet the Professor”, ACR National Meeting, Atlanta, GA
1993	Visiting Professor, Rheumatology Section, Cleveland Clinic Foundation Cleveland, Ohio
1996	American College of Rheumatology Clinical Preceptor Award
1999	Listed in “Guide to Top Doctors, 1999”
2002	Listed in “Guide to Top Doctors, 2002”
2005	Listed in “Guide to Top Doctors, 2005”
2006	Listed in Boston Magazine’s “The Top Doctors” in Rheumatology
2006	“Meet the Professor”, ACR National Meeting, Washington, D.C.
2007	Visiting Professor, Rheumatology Section, Upstate Medical Center, SUNY, Syracuse, New York
2007	Robert Dawson Evans Clinician Award (for excellence in clinical care and teaching)

2007	“Meet the Professor”, ACR National Meeting, Boston, MA
2007	Listed in Boston Magazine’s “Top Doctors” in Rheumatology
2009	Visiting Professor, Rheumatology Section, Medical College of South Carolina, Charleston, S.C.
2009	Listed in Boston Magazine’s “Top Doctors” in Rheumatology
2010	Listed in Boston Magazine’s “Top Doctors” in Rheumatology
2011	Listed in Boston Magazine’s “Top Doctors” in Rheumatology
2012	Listed in Boston Magazine’s “Top Doctors” in Rheumatology
2012	Visiting Professor, Rheumatology Section, Brown University, Providence, Rhode Island
2012	Inaugural Mary Lou Gilbane-Carolan Lectureship, Brown University
2012	Marion Ropes Award (Arthritis Foundation New England Region) for excellence in clinical care and leadership
2013	Listed in Boston Magazine’s “Top Doctors” in Rheumatology
2014	Listed in Boston Magazine’s “Top Doctors” in Rheumatology
2015	Visiting Professor, Rheumatology Section, West Penn Hospital, Pittsburgh, Pennsylvania
2015	Scleroderma Foundation: Lifetime Achievement Award
2015	Listed in Boston Magazine’s “Top Doctors” in Rheumatology
2016	Visiting Professor, Rheumatology Section, Stanford University, Stanford, CA
2016	Visiting Professor, Rheumatology Section, University of Pittsburgh, Pittsburgh, PA
2016	Listed in Boston Magazine’s “Top Doctors” in Rheumatology
2017	Listed in Boston Magazine’s “Top Doctors” in Rheumatology
2018	Listed in Boston Magazine’s “Top Doctors” in Rheumatology
2019	Listed in Boston Magazine’s “Top Doctors” in Rheumatology
2020	Listed in Boston Magazine’s “Top Doctors” in Rheumatology

Licensure and Board Certification

1980	New York #150344 (inactive)
1982	Massachusetts #50187
1985	Diplomate, American Board of Internal Medicine (#106289)
1988	Specialty Board Certification in Rheumatology (#106289)
2020	New Hampshire #20298

Principal Clinical and Hospital Service Appointments

1987 – 1997	Attending Physician, Medical Service, Boston City Hospital, Boston, MA
1987 – 1997	Attending Physician, Medical Service, University Hospital, Boston, MA
1987 – 1997	Attending Physician, Rheumatology Service, Boston City Hospital, Boston, MA

1987 – 1997	Attending Physician, Rheumatology Service, University Hospital, Boston, MA
1996 – 2001	Consulting Physician, Medical Service, Jordan Hospital, Plymouth, MA
1996 – 2020	Attending Physician, Medical Service, Boston Medical Center, Boston, MA
1996 – 2020	Attending Physician, Rheumatology Service, Boston Medical Center, Boston, MA

Educational Activities

1987 – 1990	Physical Diagnosis Instructor Medicine Clerkship, Boston City Hospital/Boston University School of Medicine
1987 – 1989	Associate Director, Medicine Clerkship, Boston City Hospital
1987 – 1996	Medical Student Faculty Advisor, Boston University School of Medicine
1992 – 1995	Integrated Problems Course, Principal Case Writer
1988 – 1992	Associated Director, Educational Activities, Boston University Multipurpose Arthritis Center
1992 – 2011	Director, Educational Activities, Boston University Multipurpose Arthritis Center
1992 – 2005	Course Director, Biology of Disease (Connective Tissue Section), Boston University School of Medicine
1994 – 2004	Co-Director, Fellowship Program in Rheumatology, Boston University Arthritis Center
2004 – 2011	Director, Fellowship Program in Rheumatology, Boston University Arthritis Center

Research Advising

Rheumatology Fellowship

Ada Man MD-Boston University
Alicia Rodriguez Pla MD-Boston University
Tom Law MD-Boston University
Ben Persons MD-Boston University
Nikki Parma MD-Dartmouth Hitchcock

Graduate Medical Sciences
Julio Montero MA

Committee Activities

International

World Scleroderma Foundation

2016 Abstract Selection Committee-4th World Scleroderma Congress

Scleroderma Clinical Trials Consortium

2007 – 2012 Treasurer (Re-elected second term 2009)

Friends of the World Scleroderma Foundation

2015 – 2018 Secretary, Member Board of Directors

International Scleroderma Network

2008 – 2010 Medical Advisory Board

National

American College of Rheumatology

1991 – 1994	Professional Meetings Committee
1992	Program Chairman, ACR Symposium on Amyloidosis, New Orleans, LA
1992	“Meet the Professor”, National Meeting, Atlanta, GA
1992	Arthroscopy Evaluation Committee
1993	Chairman, Non-Articular Rheumatism Study Group, National Meeting, San Antonio, TX
1993 – 1996	Practice Guideline Subcommittee
1994	<i>Ad Hoc</i> Grant Reviewer for Practice Guidelines
1995 – 1996	Co-Chair, Rheumatoid Arthritis Management Guidelines
1995 – 1996	Co-Chair, Rheumatoid Arthritis Treatment Monitoring Guidelines
1997	“Meet the Professor”, N.E. Regional Meeting, Boston, MA
1998	Chairman, Abstract Selection Subcommittee (Orthopedics, Soft Tissue and Regional Musculoskeletal Disease, Fibromyalgia and Sports Medicine) for National Meeting, San Diego, CA
1999	Chairman, Abstract Selection Subcommittee (Orthopedics, Soft Tissue and Regional Musculoskeletal Disease, Fibromyalgia and Sports Medicine) for National Meeting, Boston, CA
1999 – 2000	Co-Chair, Rheumatoid Arthritis Treatment Guidelines
2004	“Meet the Professor”, National Meeting, San Antonio, TX
2005	Abstract Selection Subcommittee (Systemic sclerosis, fibrosing syndromes, and Raynaud’s – clinical aspects and therapeutics), National Meeting, San Diego, CA
2006	“Meet the Professor”, National Meeting, Washington, D.C.

2006	Abstract Selection Subcommittee (Systemic sclerosis, fibrosing syndromes, and Raynaud's – clinical aspects and therapeutics), National Meeting, Washington, D.C.
2007	"Meet the Professor", National Meeting, Boston, MA
2007 – 2010	Annual Meeting Planning Committee
2008	Abstract Selection Subcommittee (Systemic sclerosis, fibrosing syndromes, and Raynaud's – clinical aspects and therapeutics), National Meeting, San Francisco, CA
2008	Moderator, The Great Debate: "Is Cyclophosphamide a Disease Modifying Agent in Scleroderma?"
2008	"Meet the Professor", Scleroderma, National Meeting, San Francisco, CA
2010 -2011	Annual Meeting Planning Committee Sub-Chair
2014	Abstract Selection Subcommittee (Systemic sclerosis, fibrosing syndromes, and Raynaud's – clinical aspects and therapeutics), National Meeting, Boston, MA

Accreditation Council for Graduate Medical Education

1997 – Present	Subspecialty Reviewer, Residence Review Committee for Internal Medicine
----------------	---

NIAMS

1994	Invited speaker, NIAMS Workshop on Fibromyalgia Syndrome
------	--

Regional

1991 – 2015	Lupus Foundation of America – Massachusetts Chapter, Medical Advisory Board
1996 – 1999	New England Rheumatism Society, Secretary/Treasurer
1999 – 2000	New England Rheumatism Society, Vice-President
2000 – 2001	New England Rheumatism Society, President
2005 – 2008	Arthritis Foundation – Massachusetts Chapter, Medical-Scientific Advisory Committee
2008 – 2015	Arthritis Foundation – Massachusetts Chapter, Board of Trustees
2008 – 2015	Arthritis Foundation – Massachusetts Chapter, Chair, Medical-Scientific Advisory Committee
2010- Present	Scleroderma Foundation-NE Region Chapter, Scientific Advisory Panel

Medical School

Boston University School of Medicine

1994 – 2005	General Clinical Research Center Protocol Review Committee
1995 – 2000	Curriculum Committee

1997	<i>Ad Hoc</i> Dean's Search Committee for Head, Office of Clinical Research
2010	<i>Ad Hoc</i> Search Committee for Gastroenterology Section Head

Hospital

1989 – Present	Internship Selection Committee, Department of Medicine
1992 – 1995	Boston City Hospital, Ambulatory Services Committee
1995 – 2008	Department of Medicine Clinical Directors Committee
1997	Department of Medicine <i>Ad Hoc</i> Promotion Committee
2008 – Present	Medical Executive Committee
2011- 2013	Department of Medicine <i>Ad Hoc</i> GI Section Head Search Committee
2012	Department of Medicine <i>Ad Hoc</i> Quality Director Search Committee
2017 -2020	Department of Medicine Promotion and Appointments Committee

Scientific Journal Reviewer

1991 – Present	<u>Arthritis and Rheumatism</u>
1991 – Present	<u>Journal of Rheumatology</u>
1992 – Present	<u>American Journal of Medicine</u>
1992 – Present	<u>Arthritis Rheumatism</u>
1994 – Present	<u>Journal of Intensive Care Medicine</u>
1995 – Present	<u>Clinical Infectious Diseases</u>
1996 – Present	<u>Annals of Rheumatic Diseases</u>
1995 – Present	<u>Scandinavian Journal of Rheumatology</u>
2005 - Present	<u>Annals of Rheumatic Disease</u>

Editorial Board Membership

1993 – 1998	<u>Amyloid: Int. J. Exp. Clin. Invest.</u>
2005 - Present	<u>Scleroderma Care and Research</u>
2012 – Present	<u>Clinical Therapeutics (Rheumatology)</u>
2016- Present	<u>Journal of Scleroderma and Related Disorders</u>

Study Section Membership

1992 - 1994	NIH <i>Ad Hoc</i> Study Section on Chronic Fatigue Syndrome
-------------	---

Current Research Interests

1. Scleroderma clinical and translational studies. Having previously led a group of clinical and translational investigators conducting therapeutic trials of novel approaches at New England's largest scleroderma referral and treatment center at Boston University, I now seek to leverage this experience to build a scleroderma treatment, referral and research center at Dartmouth.

Publications

1. SIMMS RW, Mason J, Felson D, Goldenberg DL. Tenderness in 75 anatomic sites: distinguishing fibromyalgia from controls. Arthritis Rheum 1988; 31:182-187.
2. SIMMS RW, Goldenberg D. Symptoms mimicking neurologic disorders in fibromyalgia. J Rheumatol 1988; 15:1271-1273.
3. Goldenberg DL, SIMMS RW, Geiger A, Komaroff AL. High frequency of fibromyalgia in patients with chronic fatigue seen in a primary care practice. Arthritis Rheum 1990; 33:381-387.
4. RW SIMMS, MH Coats, M Skinner, AS Cohen, RH Falk: Cardiac Involvement in Secondary Amyloidosis. In: Amyloidosis. Ed. by JB Natvig, O Forre, G Husby, A Husabekk, Skogen, K Sletten, P Westermark. Kluwer Pub., Dordrecht, The Netherlands 1990, pg. 785-788.
5. AS Cohen, M Skinner, J Anderson, RW SIMMS. Hereditary Amyloidosis Experience at Boston City Hospital Amyloid Unit: A Study of Six Distinct Greek Families. In: 1st International Symposium on Familial Amyloidotic Polyneuropathy Ed. by Costa P, et al, Arquivo de Medicina, 1990, pg. 25-28.
6. Triadafilopoulos G, SIMMS RW, Goldenberg DL. Bowel dysfunction in fibromyalgia. Dig Dis Sci 1991; 36:59-64.
7. Chalker RB, Dickey BF, Rosenthal NC, SIMMS RW. Extrapulmonary thoracic restriction ("hidebound chest") complicating eosinophilic fasciitis. Chest 1991; 100: 1453-1455.
8. SIMMS RW, Felson DT, Goldenberg DL. Development of preliminary criteria for response to treatment in fibromyalgia syndrome. J Rheumatol 1991; 18:1558-1563
9. SIMMS RW, Zerbini CAF, Ferrante N, Anthony J, Felson DT, Craven DE. Fibromyalgia syndrome in patients infected with human immunodeficiency virus. Am J Med 1992; 92:368-374.
10. Liebman HA, Carfagno MK, Weitz IC, Berard P, DiIorio JM, Vosburgh E, SIMMS RW. Excessive fibrinolysis in amyloidosis associated with elevated single chain urokinase. Am J Clin Path 1992; 98: 534-541.
11. RW SIMMS, D Goldenberg. Acute Arthritis. In: Emergency Medicine. 2nd Edition. Ed by May HL. Little, Brown, Boston, pp. 1303-1311, 1992
12. RW SIMMS. Rheumatologic Manifestations of HIV Infection. In: Clinical Manual of HIV Infection. 2nd Edition. Ed. by Libman H and Witzburg RA. Little, Brown, Boston, pp.187-197, 1993

13. Berg A, Naides SJ, SIMMS RW. Established fibromyalgia syndrome and parvovirus B19 infection. J Rheumatol 1993; 20: 1941-1943.
14. SIMMS RW, Zerbini CAF. Rheumatic disease in the intensive care unit: acute septic arthritis and temporal arteritis. J. Int. Care Med. 1993; 8: 257-274.
15. Skinner MS, Lewis WD, Jones LA, Lasirsky J, Kane K, Ju ST, Jenkins R, Falk RH, SIMMS RW, Cohen AS. Liver transplantation as a treatment for familial amyloidotic polyneuropathy: a report of five cases. Ann Intern Med 1994; 120: 133-134.
16. Rochon PA, Gurwitz JH, SIMMS RW, Fortin PR, Felson DT, Minaker KL, Chalmers TC. The relation between reported efficacy and toxicity in published trials and support of the trials by the manufacturer of the drug under evaluation. Arch Int Med 1994; 154: 157-163.
17. Lewis WD, Skinner M, SIMMS RW, Jones LA, Cohen AS, Jenkins RL. Orthotopic liver transplantation for familial amyloidotic polyneuropathy. Clin Transplantation 1994; 8: 107-110.
18. Berg A, Chipkin S, Anderson JJ, Lee V, Skinner M, Cohen AS, SIMMS RW. Autonomic neuropathy in primary amyloidosis and its effect on survival. Amyloid: Int. J. Exp. Clin. Invest. 1994; 1: 39-46.
19. SIMMS RW, Roy SH, Hrovat M, Skrinar G, LePoole SR, Zerbini CAF, DeLuca C, Jolesz F. Lack of association between fibromyalgia syndrome and abnormalities in muscle energy metabolism. Arthritis Rheum 1994; 37:794-800.
20. SIMMS RW, Prout M, Skinner M, Cohen AS. The epidemiology of AL amyloidosis: a preliminary study. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID (eds). Amyloid and Amyloidosis, 1993. New York: Parthenon, 1994, pp. 663-665.
21. Skinner M, Anderson JJ, Wang M, SIMMS RW, Falk R, Jones LA, Cohen AS. Treatment of patients with primary amyloidosis. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID (eds). Amyloid and Amyloidosis, 1993. New York: Parthenon, 1994, pp. 232-235.
22. Skinner M, Lewis WD, SIMMS RW, Jones LA, Cohen AS, Falk R, Jenkins R, Ju ST, Kane K, Kasirsky J. Liver transplantation in FAP: a report of 7 cases. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID (eds). Amyloid and Amyloidosis, 1993. New York: Parthenon, 1994, pp. 441-443.
23. SIMMS RW, Falk R, Skinner M, Cohen AS. Cardiac transplantation in AL amyloidosis: experience in three patients. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID (eds). Amyloid and Amyloidosis, 1993. New York: Parthenon, 1994, pp. 645-647.

24. SIMMS RW, Cohen AS. Epidemiology of AL and AA amyloidosis. Balliere's Clin Rheumatol 1994; 8: 627-634.
25. SIMMS RW. Controlled trials of therapy in fibromyalgia syndrome. In: Masi AT (ed) Fibromyalgia and Myofascial Pain Syndromes. Balliere's Clin Rheumatol 1994; 8: 917-935.
26. SIMMS RW. Therapy of fibromyalgia syndrome. In: Weisman M, Weinblatt ME (eds) Treatment of Rheumatic Disease Philadelphia, WB Saunders, 1994, pp. 16-30.
27. SIMMS RW. Muscle studies in fibromyalgia syndrome. J Musculoskeletal Pain 1994; 2: 117-123.
28. SIMMS RW, Cahill L, Prashker M, Meenan RF. The direct costs of fibromyalgia treatment: comparison with rheumatoid arthritis and osteoarthritis. J Musculoskeletal Pain 1995; 3: 127-132.
29. Gravallese EM, Waksmonski C, Winters G, SIMMS RW. Fever, arthralgia, skin lesions and ischemic digits in a fifty-nine year old man. Arthritis Rheum 1995; 38: 1161-1168.
30. Dubrey S, SIMMS RW, Skinner M, Falk RH. Recurrence of primary (AL) amyloidosis in transplanted heart with a 4 year survival. Am J Cardiol 1995; 76: 739-741.
31. Fraenkel L, Gibbons D, SIMMS RW. The clinical significance of liver disease in systemic lupus erythematosus: a case report and review of the literature. Clinical Rheumatology 1996; 2: 23-28.
32. Skinner M, Anderson JJ, SIMMS RW, Falk R, Libbey C, Jones LA. Randomized trial of treatment for primary (AL) amyloidosis. Am J Med 1996; 290-298.
33. Berg A, Kasznica J, Hopkins P, SIMMS RW. Relapsing polychondritis and aseptic meningitis. J Rheumatol 1996; 23: 567-569.
34. Wolfe F, Bennett RM, Bombardier D, Broadhurst N, Cameron RS, Carrette S, Chalmers A, Cohen M, Crook J, Ehrlich G, Fam A, Gillies J, Goldenberg D, Hendriksson KG, Janda V, Littlejohn G, McCain GA, Mease P, Moldofsky H, Olin R, Pontinen PJ, Puttick M, Raspe H, Reilly PA, Reynolds J, Rice JR, Romano TJ, Russell IJ, Silerman S, SIMMS RW, Smythe H, Tunks E, Ulsan D, Yunus MB. The fibromyalgia syndrome: a consensus report on fibromyalgia and disability. J Rheumatology 1996; 23: 534-539.
35. Kwok K, SIMMS RW, Anderson L, Erlandson DM, Greene JM, Kelleher M, Moncur D, O'Dell J, Partridge A, Roberts WN, Robbins ML, Yood RA, Liang MH. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 713-722.

36. SIMMS RW, Kwoh K, Anderson L, Erlandson DM, Greene JM, Kelleher M, Moncur D, O'Dell J, Partridge A, Roberts WN, Robbins ML, Yood RA, Liang MH. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39: 723-731.
37. Dubrey SW, Cha K, SIMMS RW, Skinner M, Falk RH. Electrocardiography and doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol 1996; 77: 313-315.
38. SIMMS RW. Is there muscle pathology in fibromyalgia syndrome? Rheum Dis Clin N Am 1996; 22: 245-266.
39. SIMMS RW. Fibromyalgia syndrome: current concepts in pathophysiology, clinical features and management. Arthritis Care Res 1996; 9: 315-328.
40. Comenzo RL, Vosburgh E, SIMMS RW, Bergethon P, Sarnicki D, Finn K, Dubrey SW, Wright DG, Falk RH, Skinner M. Dose-intensive melphalan with blood stem-cell support for the treatment of AL amyloidosis. Blood 1996; 88: 2801-2806.
41. Bergethon PR, Sabin TD, Lewis D, SIMMS RW, Cohen AS, Skinner M. Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation. Neurology 1996; 47: 944-951.
42. SIMMS RW. Regional disorders of the lower extremities. In: PJ Maddison, DA Isenberg, P Woo, DN Glass (eds). Oxford Textbook of Rheumatology (2nd edition). Oxford University Press, Oxford, 1998, pp. 1-28.
43. Polisson RP, Moore M, Anderson P, Gilkerson G, Harris N, Kay J, Khan M, Manzi S, SIMMS RW, Simon L. Medical Knowledge Self-Assessment Program (MKSAP) in the Subspecialty of Rheumatology. American College of Physicians. Philadelphia. 1997, pp.1-403.
44. SIMMS RW. Arthropathies associated with hematologic and malignant disorders. Primer on the Rheumatic Diseases. Eleventh Edition. Ed.by R.L. Wortmann. Arthritis Foundation. Atlanta, 1997, pp. 335-338.
45. SIMMS RW, Kwoh CK, Anderson LG, Erlandson DM, Greene JM, Moncur C, O'Dell JR, Partridge AJ, Roberts WN, Robbins ML, Yood RA, Liang MH. ACR practice guidelines. Arthritis Rheum 1997; 40: 391-392 (lett)
47. Powsner RA, SIMMS RW, Chudnovsky A, Lee VW, Skinner M. Scintigraphic functional hyposplenism in amyloidosis. J Nuc Med 1998; 39: 221-223.
48. SIMMS RW. Fibromyalgia is not a muscle disorder. In: Advances in Fibromyalgia. Ed. by G. Alarcon, L.A. Bradley. Am J Med Sci 315: 346-350.
49. SIMMS RW. Treatment of fibromyalgia. Rheumatology and Musculoskeletal Medicine for Primary Care. 1998; 1: 19-26.

50. SIMMS RW, Kirby RE. Case Records of the Massachusetts General Hospital. A 64-year-old man with cranial-nerve palsies and a positive test for antinuclear cytoplasmic antibodies. N Engl J Med 1998; 339: 775-763.
51. Wigley FM, Korn JH, Csuka E, Medsger TA, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez S, Mayes M, Merkel PH, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, SIMMS RW, Phillips AC, Seibold JR. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998; 41: 670-677.
52. Klings E, Hill NS, Leong MH, SIMMS RW, Korn JH, Farber HW. Systemic sclerosis associated pulmonary hypertension: acute and long-term effects of epoprostenol (prostacyclin). Arthritis Rheum 1999; 42: 2638-2645
53. Amin S, LaValley MP, SIMMS RW, Felson DT. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 1999; 42: 1740-1751.
54. SIMMS RW. Fibromyalgia syndrome. In: Diseases of Skeletal Muscle. Ed. by R.L. Wortmann. Lippincott, Philadelphia, 2000, pp.221-244.
55. Siebold JR, Korn JH, SIMMS RW, Clements PJ, Moreland LW, Mayes MD, Furst DE, Rothfield N, Steen V, Weisman M, Collier D, Wigley FM, Merkel PA, Csuka M, Hsu V, Rocco S, Erikson M, Hannigan J, Harkonen S, Sanders M. Recombinant human relaxin in the treatment of scleroderma: a randomized double-blind, placebo-controlled multicenter trial. Ann Int Med 2000; 132: 871-879.
56. SIMMS RW. Idiopathic inflammatory myopathies. In: Andreoli TE, Carpenter CCJ, Griggs RC, Loscalzo J (eds). Cecil's Essentials of Medicine (5th edition). W.B. Saunders, Philadelphia, 2001, 694-697.
57. SIMMS RW. Nonarticular soft tissue disorders. In: Andreoli TE, Carpenter CCJ, Griggs RC, Loscalzo J (eds). Cecil's Essentials of Medicine (5th edition). W.B. Saunders, Philadelphia, 2001, 715-719.
58. SIMMS RW. Osteoarthritis. In: Andreoli TE, Carpenter CCJ, Griggs RC, Loscalzo J (eds). Cecil's Essentials of Medicine (5th edition). W.B. Saunders, Philadelphia, 2001, 712-714.
59. SIMMS RW. Rheumatic manifestations of systemic disorders. In: Andreoli TE, Carpenter CCJ, Griggs RC, Loscalzo J (eds). Cecil's Essentials of Medicine (5th edition). W.B. Saunders, Philadelphia, 2001, 720-724.
60. SIMMS RW. Soft Tissue Disorders: Diagnosis and Management. Lippincott, Williams and Wilkins, Philadelphia, pp.1-106, 2001

61. SIMMS RW. Bursitis, tendonitis, myofascial pain and fibromyalgia. In: Rakel RE, Bope ET (eds). Conn's Current Therapy (53rd edition) WB Saunders, Houston, pp. 1028-1031, 2001
62. SIMMS RW, Korn JH. Systemic sclerosis: the spectrum, immunopathogenesis, clinical features and treatment. In: Madaio MP, Adu D, Emery P(eds). Rheumatology and the Kidney. Oxford University Press, Oxford, UK, pp.275-292, 2001
63. Kwok CK, Anderson LG, Greene JM, Johnson DA, O'Dell JR, Robbins ML, Roberts WN, SIMMS RW, Yood RA. Guidelines for the management of rheumatoid arthritis, 2002 update. *Arthritis Rheumatism* 42: 328-346, 2002
64. SIMMS RW. Arthropathies associated with hematologic and malignant disorders. Primer on the Rheumatic Diseases. Twelfth Edition. Ed. by. J.H. Klippel. Arthritis Foundation. Atlanta, 2001, pp. 335-338.
65. Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, SIMMS RW, Csuka ME, Medsger TA, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jimenez SA, White B, Seibold JR, Wigley FM. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 46: 2410-2420, 2002
66. SIMMS RW, Korn JH. Cytokine directed therapy in scleroderma: rationale, current status, and the future. Curr Opin Rheumatol 14: 717-722, 2002
67. Zerbini CA, Anderson JJ, Kane KA, Ju ST, Campistol JM, SIMMS RW, Cohen AS, Skinner M. Beta-2 microglobulin serum levels and prediction of survival in AL amyloidosis. Amyloid: J. Protein Folding Disord 9: 242-246, 2002
68. Amin S, Lavalley MP, SIMMS RW, Felson DT. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Min Res 17:1512-26, 2002
69. SIMMS RW, Korn JH. The role of leukotrienes in alveolitis associated with scleroderma. Arthritis Rheum 48: 1478-1480, 2003
70. Korn, JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick, Merkel PA, SIMMS RW, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50: 385-3993, 2004
71. Moreland LW(ed) Rheumatology and Immunology Therapy: A to Z Essentials. Abbott JD, Ball G, Boumpas D, Bridges SL, Chatam W, Curtis J, Daniel, C, Hughes LB, Kao AH, Langford C, Lovell D, Manzi S, Muller-Ladner U, Patel HC, Roubey RAS, Saag K, Sabatine JM, Shanahan J, SIMMS RW, Smith E, Sundry J, Szalai A, Wimmer T.

Springer-Verlag, Berlin, 2004

72. SIMMS RW, Herrick AL. New therapies for pulmonary arterial hypertension associated with systemic sclerosis. Scleroderma Care & Research 3: 14- 20, 2005
73. Kissin EY, Schiller AM, Gelband RB, Anderson JJ, Falanga V, SIMMS RW, Korn JH, Merkel PA. Durometry for the assessment of skin disease in systemic sclerosis. Arthritis Rheum 55: 603-609, 2006
74. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst D, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, SIMMS R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Murabak K, Connelly K, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Springmeyer S. The scleroderma lung study: oral cyclophosphamide versus placebo for the treatment of scleroderma-related interstitial lung disease. N Eng J Med 354: 2655-2665, 2006
75. Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, Sterz M, Seibold JR, Schraufnagel D, SIMMS RW, Bolster M, Wise RA, Steen V, Mayes MD, Connolly K, Metersky M, Furst DE. Scleroderma lung study: differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 10:1136, 2007
76. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst D, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, SIMMS R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Murabak K, Connelly K, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Khanna D, Li N, Li G. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Resp Clin Care Med, 176: 1026-34, 2007
77. Tashkin DP, Elashoff R, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, SIMMS R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ. Impact of Oral Cyclophosphamide on Health-Related Quality of Life in Patients with Scleroderma Lung Disease with Active Alveolitis. Arthritis Rheum 56(5): 1676-84, 2007
78. Postlethwaite, AE., Wong, WK, Clements P, Chatterjee S, Fessler BJ, Kang, A H, Korn, J, Mayes, M, Merkel, PA, Molitor J, Moreland L, Rothfield N, SIMMS, RW, Smith EA, Spiera R, Steen V, Warrington K, White B, Wigley F, Furst D. A multicenter, randomized, double-blind, placebo-controlled trial of oral type collagen treatment in patients with diffuse cutaneous systemic sclerosis. I. Oral CI does not improve skin in all patients but may improve skin in late disease. Arthritis Rheum 58 (6): 1810-1822, 2008
79. Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N,

- Steen V, Martin R, Smith E, Mayes M, SIMMS RW, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Gilbert A, Dechow FJ, Gregory J, Wigley FM. MQX-503, A novel formulation of nitroglycerin improves severity of raynaud's phenomenon: a randomized controlled trial. Arthritis Rheum 60 (3): 870-877, 2009
80. Khanna D, Clements P, Mayes M, Merkel P, Mellman , SIMMS RW, Sanders M, Rothfield N, Steen V, Moreland L, Kavanaugh A, Weisman M, Firestein G, Collier D, Silver R, Wigley F, Csuka ME, Medsger T, Seibold J, Maranian P. A randomized, double-blind, placebo-controlled trial of recombinant human relaxin in the treatment of systemic sclerosis with diffuse scleroderma. Arthritis Rheum 60 (4): 1102-1111, 2009
 81. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel P, SIMMS RW. B cell depletion in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60 (2): 578:583, 2009
 82. Radstake TR, van Bon L, Broen J, Hussiani A, Hesselstrand R, Wuttge DM, Deng Y, SIMMS RW, Lubberts E, Lafyatis R. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One 4(6):e5903, 2009
 83. Radstake TR, van Bon L, Broen J, Wenink M, Santegoets K, Deng Y, Hussaini A, SIMMS RW, Cruikshank WW, Lafyatis R. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PLoS One 4(6):e5981, 2009
 84. Van Bon L, Popa C, Huijbens R, Vonk M, York M, SIMMS R, Hesselstrand R, Wuttge DM, Lafyatis R, Radstake TR. Distinct evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 69 (8)L 1539-47, 2010
 85. SIMMS RW, Lafyatis R. Rituximab: a potential therapeutic advance in scleroderma Rheumatology(Oxford) 49 (2): 271-80, 2010.
 86. Farber H, SIMMS RW, Lafyatis R. Scleroderma. Care of patients with scleroderma in the intensive care setting. J Intensive Care Med, 25: 247-58, 2010 .
 87. SIMMS RW. Localized scleroderma and scleroderma-like syndromes. In Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds), Rheumatology 5th ed. Philadelphia, PA; Mosby Elsevier; 2011: 1433-1438.
 88. Khanna D, Kowal-Bielecka O, Khanna P, Lapinska A, Asch SM, Wenger N, Brown K, Clements P, Getzug T, Mayes MD, Medsger T, Oudiz R, SIMMS RW, Steen V, Maranian P, Furst DE. Quality indicator set for systemic sclerosis. Clin Exp Rheumatol 229 (2 Suppl 65): S33-9, 2011

89. Sharif R, Fritzler SR, Mayes MD, Gonzalez EB, McNearney TA, Draeger H, Baron H, Furst DE, Khanna DK, Del Junc DJ, Molitor JA, Schioppa E, Phillips K, Seibold JR, Silver RM, SIMMS RW, Perry M, Rojo C, Charles J, Zhou X, Agarwal SK, Reveille JD, Assassi S, Arnett FC. Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis. J Rheumatol 38(8): 1622-30, 2011
90. Man A, Zhu Y, Zhang Y, Dubreuil M, Rho YH, Peloquin C, SIMMS RW, Choi, HK. The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study Ann Rheum Dis 72: 1188-93, 2013
91. Hung EW, Mayes MD, Sharif R, Assassi S, Machicao VI, Hosing C, St Clair EW, Furst DE, Khanna D, Forman S, Mineishi S, Phillips K, Seibold JR, Bredeson C, Csuka ME, Nash RA, Wener MH, SIMMS R, Ballen K, Leclercq S, Storek J, Goldmuntz E, Welch B, Keyes-Elstein L, Castina S, Crofford LJ, Mcsweney P, Sullivan KM. Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial. J Rheumatol 40(4): 455-60, 2013
92. van den Hoogen F, Khanna D, Fransen J, Johnson S, Baron M, Tyndall A, Matucci-Cerinic M, Naden R, Medsger TA, Carriera P, Riemekasten G, Clements P, Denton C, Distler O, Allanore Y, Furst D, Gabrielli A, Mayes M, van Laar J, Seibold J, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka U, Chung L, Collier D, Csuka M, Fessler B, Guiducci S, Herrick A, Hsu V, Jimenez S, Kahaleh B, Merkel P, Sierakowski S, Silver R, SIMMS R, Varga J, Pope J. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative initiative. Arthritis Rheum, 65: 2737-47, 2013
93. Christman R, Stifano G, Borges C, de Carvalho C, Bonfa E, Sampaio-Barros P, Parra E, Spira A, SIMMS RW, Capellozzi VL, Lafyatis R. Key roles for interferon and TGF beta regulated genes and macrophage activation in progressive lung fibrosis associated with systemic sclerosis. Arthritis Rheumatol 66: 714-725, 2014
94. Chung L, Domsic R, Lingala B, Alkassab F, Bolster M, Csuka ME, Derk C, Fischer A, Frech T, Furst D, Gomberg-Maitland M, Hinchcliff M, Hsu V, Hummers L, Khanna D, Medsger T, Molitor J, Preston I, Schioppa E, Shapiro L, Silver R, SIMMS RW, Varga J, Gordon J, Steen V. Survival and predictors of mortality in systemic sclerosis associated pulmonary arterial hypertension: outcomes from the PHAROS Registry. Arthritis Care and Res, 66: 489-95, 2014
95. Kissin EY, Garg A, Grayson PC, Dubreuil M, Vradii D, York M, SIMMS RW. Ultrasound assessment of subcutaneous compressibility: a potential adjunctive diagnostic tool in eosinophilic fasciitis. J Clin Rheumatol 19: 382-5, 2013
96. van den Hoogen F, Khanna D, Fransen J, Johnson S, Baron M, Tyndall A, Matucci-Cerinic M, Naden R, Medsger TA, Carriera P, Riemekasten G, Clements P, Denton C,

- Distler O, Allanore Y, Furst D, Gabrielli A, Mayes M, van Laar J, Seibold J, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka U, Chung L, Collier D, Csuka M, Fessler B, Guiducci S, Herrick A, Hsu V, Jimenez S, Kahaleh B, Merkel P, Sierakowski S, Silver R, Simms R, Varga J, Pope J. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative initiative. *Ann Rheum Dis* 72: 1747-55, 2013
97. Goldberg A, Geppert T, Schiopu E, Frech T, Hsu V, SIMMS R, Peng SL, Yao Y, Elgeioushi N, Chang L, Wang B, Yoo S. Dose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. *Arthritis Res & Therapy* 16: R57, 2014
 98. Mayes MD, Bossini-Castillo L, Gorlova O, Martin JE, Zhou X, Chen WV, Assassi S, Ying J, Filemon TK, Arnett FC, Reveille JD, Guerra S, Teruel M, Carmona FD, Gregersen PK, Lee AT, Lopez-Isac E, Ochoa E, Carreira P, Simeon CP, Castillvi I, Gonzalez-Gay MA, the Spanish Scleroderma Group, Zhernakova A, Padyukov L, Alarcon-Riquelme M, Wijmenga C, Brown M, Beretta L, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Distler JHW, Voskuyl AE, Schuerwegh AJ, Hesselstrand R, Nordin A, Airo P, Lunardi C, Sheils P, van Laar JM, Herrick A, Worthinton J, Denton C, Wigley RM, Hummers LK, Varga J, Hinchcliff ME, Baron M, Hudson M, Pope JE, Furst DE, Khanna D, Phillips K, Schiopu E, Segal BM, Molitor JA, Silver RM, Steen VD, SIMMS RW, Lafyatis RA, Fessler BJ, Frech TM, Alkassab F, Docherty P, Kaminsak E, Khalidi N, Jones HN, Markland J, Robinson D, Broen J, Radstake T, Fonseca C, Koелеman BP, Martin J. Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. *Am J Human Genetics* 94: 47-61, 2014
 99. Hsu VM, Chung L, Hummers L, Wigley F, SIMMS RW, Bolster M, Silver R, Fischer A, Hinchcliff ME, Varga J, Goldberg A, Derk CT, Schiopu E, Khanna D, Shapiro LE, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Alkassab F, Steen VD. Development of pulmonary hypertension in a high risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. *Sem Arthritis Rheum* 44: 55-62, 2014
 100. Gopal DM, Doldt B, Finch K, SIMMS RW, Farber HW, Gokce N. Relation of novel echocardiographic measures to invasive hemodynamic assessment in scleroderma-associated pulmonary arterial hypertension. *Arthritis Care Res* 66(9): 1386-94, 2014
 101. SIMMS RW. Localized scleroderma and scleroderma-like syndromes. In Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds), *Rheumatology* 6th ed. Philadelphia, PA; Mosby Elsevier; 2014: 1219-1223.
 102. Fischer A, Swigris JJ, Bolster M, Chung L, Csuka ME, Domsic R, Frech T, Hinchcliff M, Hsu V, Hummers LK, Gombert-Maitland M, Mathai SC, SIMMS RW, Steen VD. Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent

of fibrosis and pulmonary physiology on cardiac hemodynamic parameters. Clin and Exp Rheumatology 32 (6 Suppl 86): S109-14, 2014

103. Salazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M, Khanna D, Schiopus E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Taillefer SS, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, SIMMS RW, Silver RM, Frech TM, Fessler BJ, Molitor JA, Fritzler MJ, Segal BM, Al-Kassab F, Perry M, Yang J, Zamanian S, Reveille JD, Arnett FC, Pedroza C, Mayes MD. Antinuclear antibody negative systemic sclerosis. Sem Arthritis Rheum 2014 Nov 28 [Epub ahead of print]
104. Man A, Davidyock T, Western L, Jeong MH, Zhang Y, SIMMS RW. Changes in forced vital capacity over time in systemic sclerosis: application of group based trajectory modeling. Rheumatology (Oxford) 54: 1464-1471, 2015
105. Pope J, Mayes M, Distler O, Denton C, Trojanowska M, SIMMS RW, Varga J. Systemic Sclerosis. Nature Reviews Disease Primers 2015 (in press)
106. Rice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemk J, Goummih S, Nakerakanti S, York M, Farina G, Whitfield ML, Spiera RF, Christman RB, Gordon JK, Weinberg J, SIMMS RW, Lafyatis R. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 125: 2795-807, 2015
107. Rice LM, Ziemack J, Stratton E, Mclaughlin S, Padilla C, Mathes A, Christmann R, Stifano G, Browning J, Whitfield M, Spiera R, Gordon J, SIMMS RW, Zhang Y, Lafyatis R. A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 67: 3004-3015, 2015
108. Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen V, Assassi S, Schiopus E, Phillips K, SIMMS RW, Allanore Y, Denton CP, Distler O, Johnson SR, Matucci-Cerinic M, Pope JE, Proudman SM, Siegel J, Wong WK, Wells AU, Furst DE. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 68(2):299-311, 2016
109. Wu M, Assassi S, Salazar GA, Pedroza C, Gorlova OY, Chen WV, Charles J, Taing ML, Liao K, Wigley FM, Hummers LK, Shah AA, Hinchcliff M, Khanna D, Schiopus E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Zhou X, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, SIMMS RW, Silver RM, Frech TM, Fessler BJ, Fritzler MJ, Molitor JA, Segal BM, Movahedian M, Martín J, Varga J, Mayes MD. Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients Arthritis Res Ther. 20;18(1):20, 2016
110. Ziemek J, Man A, Hinchcliff M, Varga J, SIMMS RW, Lafyatis R. The relationship between skin symptoms and the scleroderma modification of the health assessment

- questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis. *Rheumatology (Oxford)*. 55:911-7, 2016
111. Van Laar JM, SIMMS RW. Immunomodulatory, Immunoablative and Biologic Therapies. In Varga J, Denton C, Wigley F (eds), *Scleroderma: From Pathogenesis to Comprehensive Management (2nd Ed)*; Springer Science, 2016
 112. SIMMS RW. Assessment and Management of Progressive Skin Disease in Scleroderma. In Varga J, Denton C, Wigley F (eds), *Scleroderma: From Pathogenesis to Comprehensive Management (2nd Ed)*; Springer Science, 2016
 113. Christmann RB, Wooten A, Sampaio-Barros P, Borges CL, Carvalho CR, Kairalla RA, Feghali-Bostwick C, Ziemek J, Goumih S, Tan J, Alvarez D, Kas DJ, Rojas M, de Mattos TL, Parra E, Stifano G, Capelozzi VL, SIMMS RW, Lafyatis R. miR-155 in the progression lung fibrosis in systemic sclerosis. *Arthritis Res Ther* 18 (1): 155, 2016
 114. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GH, Tseng CH, Elashoff RM; Scleroderma Lung Study II Investigators. cyclophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial *Lancet Respir Med*. Sep;4(9):708-19. doi: 10.1016/S2213-2600(16)30152-7, 2016
 115. Ziemek J, Man A, Hinchcliff M, Varga J, Simms RW, Lafyatis R. The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis. *Rheumatology (Oxford)*. May;55(5):911-7. doi: 10.1093/rheumatology/kew003, 2016
 116. Chung L, Fairchild RM, Furst DE, Li S, Alkassab F, Bolster MB, Scuka ME, Derk CT, Domsic RT, Fischer A, Frech T, Gomberg-Maitland M, Gordon JK, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TA, Molitor JA, Preston IR, Schioppa E, Shapiro L, Handt F, Silver R, SIMMS RW, Varga J, Steen VD, Zamanian RT. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. *Clin Exp Rheumatol* Nov 10 [Epub ahead of print], 2016
 117. Rice LM, Mantero JC, Stifano G, Ziemek J, Simms RW, Gordon J, Domsic R, Lafyatis R. A proteome-derived longitudinal pharmacodynamics biomarker for diffuse systemic sclerosis skin. *J Invest Dermatol*. Jan;137(1):62-70, 2017

118. Law ST, Farber HW, SIMMS RW. Use of intravenous epoprostenol as a treatment for the digital vasculopathy associated with the scleroderma spectrum of diseases. *J Scleroderma Related Dis* 2 (3): 208-212, 2017
119. Man A, SIMMS RW, Felson DT, Lafyatis R Development and validation of a patient reported outcome instrument for skin involvement in patients with systemic sclerosis *Ann Rheum Dis* Feb 17. pii: annrheumdis-2016-210534. doi: 10.1136/annrheumdis-2016-210534. [Epub ahead of print], 2017
120. Toyama T, Looney AP, Baker BM, Stawski, L Haines P, SIMMS RW, Szmaniak AD, Varelas X, Trojanowska, M. Therapeutic targeting of TAZ and YAP by dimethyl fumarate in systemic sclerosis fibrosis. *J Invest Dermatol* Sep1 pii S0022-202X (17) 32919-6 [Epub ahead of print], 2017
121. Lafyatis R, Mantero JC, Gordon J, Kishore N, Cams M, Dittrich H, Spiera R, Simms RW, Varga J. Inhibition of beta-catenin signaling in the skin rescues cutaneous adipogenesis in systemic sclerosis: a randomized, double blind placebo controlled trial of C-82. *J Invest Dermatol* Aug 11[Epub ahead of print], 2017
122. Mantero J, Kishore N, Ziemek J, Stifano G, Khanna D, Zhang Y, Simms RW, Lafyatis R. Randomized, double-blind, placebo-controlled trial of IL-1 trap, rilonacept in systemic sclerosis-a phase I/II biomarker trial (Submitted, 2017)
123. Makino K, Makino T, Stawski, Mantero JC, Lafyatis R, Simms R, Trojanowska M. Blockade of PDGF receptors by crenolanib has therapeutic effect in patient fibroblasts and in preclinical models of systemic sclerosis. *J Invest Dermatol* Aug; 137 (8): 1671-1681, 2017
124. Law ST, Farber HW, SIMMS RW. Use of intravenous epoprostenol as a treatment for the digital vasculopathy associated with the scleroderma spectrum of diseases. *J Scleroderma Relat Disord* 2: 208-212, 2017
125. Seibold, JR, Wigley FM, Schioppa E, Denton CP, Silver RM, Steen VD, Domsic R, Medsger TA, Mayes, MD, Chatterjee S, Chung L, Csuka ME, Khanna D, Collier D, Frech TM, Molitor JA, Rothfield N, Herrick AL, SIMMS R, Pope JE, Baron M, SHsu VM, Peng SL, Spiera R, Fessler BJ, Kahaleh B, Varga J, Laliberte K, Wade M, Rollins K. Digital ulcers in SSc treated with oral treprostinil: a randomized, double-blind, placebo-controlled study with open-label follow-up. *J Scleroderma Related Disorders* 2: 42-49, 2017
126. Gorlova OY, Li Y, Gorlov I, Ying J, Chen WV, Assassi S, Reveille JD, Arnett FC, Zhou X, Bossini-Castillo L, Lopez-Isac E, Acosta-Herrera M, Gregersen P, Lee AT, Steen VD, Fessler BD, Khanna D, Schioppa E, Silver RM, Molitor JM, Furst DE, Kafaja S, SIMMS RW, Lafyatis RA, Carreira P, Simeon CP, Castellvi I, Beltran E, Ortego N, Amos CI, Martin J, Mayes MD. Gene-level analysis of systemic sclerosis: a comparison of African-Americans and White populations. *Plos One* 13(1) Jan2, 2018

127. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein D, Wallace D, Cracionescu O, Khanna D, Goldin J, Folz R, St Clair W, Seibold JR, Phillips K, Mineshi S, SIMMS RW, Ballen K, Wener M, Georges G, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClerq S, Lohr K, Brasington R, Czuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE. Myeloablative autologous stem cell transplantation for severe scleroderma, *NEJM* 378:35-47, 2018.
128. Rice LM, Mantero JC, Stratton EA, Warburton R, Roberts K, Hill N, SIMMS RW, Domsic R, Farber HW, Lafyatis R. Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis *Arthritis Res Ther.* 16;20(1):185: 1675-8, 2018
129. Fleury M, Belkina AC, Proctor EA, Zammitti C, SIMMS RW, Lauffenburger DA, Snyder-Cappione JE, Lafyatis R, Dooms H. Increased expression and modulated regulatory activity of coinhibitory receptors PD-1, TIGIT and TIM-3 in lymphocytes from patients with systemic sclerosis. *Arthritis Rheumatol* 2018 Apr; 70(4): 566-577.
130. Mantero JC, Kishore N, Ziemek J, Stifano G, Zammitti C, Khanna D, Gordon JK, Spiera R, Zhang Y, SIMMS RW, Lafyatis R. Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial. *Clin Exp Rheumatol.* 113(4):146-149, 2018
131. Messemaker TC, Chadli L , Cai G, Goelela GS , Boonstra M , Dorje A , Andersen SN , Mikkers HM, van 't Hof P , Mei H , Distler O, Draisma HH, Johnson M , Orzechowski NM, SIMMS RW, Toes RE , Aarbiou J, Huizinga TW, Whitfield MT, DeGroot J, de Vries-Bouwstra J, Kurreeman F. *J Invest Dermatol* 2018 Apr;138(4):826-835.
132. Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, Pauciulo MW, Hadinnapola C, Aman J, Girerd B, Arora A, Knight J, Hanscombe KB, Karnes JH, Kaakinen M, Gall H, Ulrich A, Harbaum L, Cebola I, Ferrer J, Lutz K, Swietlik EM, Ahmad F, Amouyel P, Archer SL, Argula R, Austin ED, Badesch D, Bakshi S, Barnett C, Benza R, Bhatt N, Bogaard HJ, Burger CD, Chakinala M, Church C, Coghlan JG, Condliffe R, Corris PA, Danesino C, Debette S, Elliott CG, Elwing J, Eyries M, Fortin T, Franke A, Frantz RP, Frost A, Garcia JGN, Ghio S, Ghofrani HA, Gibbs JSR, Harley J, He H, Hill NS, Hirsch R, Houweling AC, Howard LS, Ivy D, Kiely DG, Klinger J, Kovacs G, Lahm T, Laudes M, Machado RD, MacKenzie Ross RV, Marsolo K, Martin LJ, Moledina S, Montani D, Nathan SD, Newnham M, Olschewski A, Olschewski H, Oudiz RJ, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Rehman Z, Robbins I, Roden DM, Rosenzweig EB, Saydain G, Scelsi L, Schilz R, Seeger W, Shaffer CM, SIMMS RW, Simon M, Sitbon O, Suntharalingam J, Tang H, Tchourbanov AY, Thenappan T, Torres F, Toshner MR, Treacy CM, Vonk Noordegraaf A, Waisfisz Q, Walsworth AK, Walter RE, Wharton J, White RJ, Wilt J, Wort SJ, Yung D, Lawrie A, Humbert M, Soubrier F, Tréguët DA, Prokopenko I, Kittles R, Gräf S, Nichols WC, Trembath RC, Desai AA,

- Morrell NW, Wilkins MR; UK NIHR BioResource Rare Diseases Consortium; UK PAH Cohort Study Consortium; US PAH Biobank Consortium. Genetic determinants of risk of pulmonary arterial hypertension: international genome-wide association studies and meta-analysis *Lancet Respir Med* 7(3):227-238, 2019
133. Johnson ME, Franks JM, Cai G, Mehta BK, Wood TA, Archambault K, Pioli PA, SIMMS RW, Orzechowski N, Arron S, Whitfield ML Microbiome dysbiosis is associated with disease duration and increased inflammatory gene expression in systemic sclerosis skin. *Arthritis Res Ther.* 6;21(1):49, 2019
 134. Rodriguez-Pla A, SIMMS RW. Geographic disparity in systemic sclerosis mortality in the United States: 1999-2017. *J Scleroderma Related Dis* First Published 26 Aug 2019. <https://doi.org/10.1177/2397198319869566>
 135. Khanna D, Spino C, Johnson S, Chung L, Whitfield M, Denton CP, Berrocal V, Franks J, Mehta B, Molitor J, Steen VD, Lafyatis R, Simms RW, Gill A, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Schioppa E, Young A, Sandorfi N, Park J, Hant FN, Bernstein EJ, Chatterjee S, Castellino FV, Ajan A, Wang Y, Wood T, Allanore Y, Matucci-Cerinic M, Distler O, Singer O, Bush E, Fox D, Furst DE. Abatacept in early diffuse cutaneous systemic sclerosis-results of a phase 2 investigator-initiated, multicenter, double-blind placebo controlled trial. *Arthritis Rheumatol* 72(1): 125-136, 2020
 136. Simms RW. Expert perspectives on clinical challenges. *Arthritis Rheumatol.* Sep; 72(9): 1415-1426, 2020

Abstracts

1. SIMMS RW, Mason J, Felson D, Goldenberg DL. Tenderness in 75 anatomic sites: distinguishing fibromyalgia from controls. Arthritis Rheum 1986; 29:S88.
2. SIMMS RW, Smith B, Skinner M, Cohen AS. Detection of circulating monoclonal B-cell excess in primary amyloidosis. Arthritis Rheum 1987; 20:S9.
3. SIMMS RW, Goldenberg DL. Peripheral neuropathic symptoms in fibromyalgia. Arthritis Rheum 1987; 30:S51.
4. SIMMS RW, Felson DR, Goldenberg DL. Criteria for response to treatment in fibromyalgia. Arthritis Rheum 1988; 31:S100.
5. SIMMS RW, Gunderman J, Howard G, Goldenberg DL. The alpha-delta sleep abnormality in fibromyalgia. Arthritis Rheum 1988; 31:S100.
6. Goldenberg DL, SIMMS RW, Geiger A, Komaroff A. Most patients with chronic fatigue syndrome have fibromyalgia. Arthritis Rheum 1989; 32:S47.
7. Mason JH, SIMMS RW, Goldenberg DL, Meenan RF. The impact of fibromyalgia on work: A comparison with RA. Arthritis Rheum 1989; 32:S46.
8. Falk RH, Fuchs T, Skinner M, SIMMS RW, Cohen AS. Electrophysiologic abnormalities in primary cardiac amyloidosis. J Am Coll Cardiol 1990; 15:124A
9. Cohen AS, Skinner M, Anderson J, SIMMS RW. Six Greek kindreds with familial amyloid polyneuropathy. Arquivos de Medicina 1989; 3:188.
10. SIMMS RW, Ferrante N, Craven D. High prevalence of fibromyalgia syndrome in human immunodeficiency virus type I infected patients with polyarthralgia. Arthritis Rheum 1990; 33: S 136.
11. SIMMS RW, Roy S, Skrinar G, Hrovat M, Anderson JJ, Kimmels A, Zerbini CF, DeLuca C, Jolesz F. ³¹P-NMR spectroscopy of muscle in fibromyalgia syndrome patients and sedentary controls. Arthritis Rheum 1991; 34:S189.
12. Berg A, Nades SJ, SIMMS RW. Established fibromyalgia syndrome and parvovirus B19 infection. Arthritis Rheum 1992; 35:R41.
13. SIMMS RW, Roy SH, Hrovat M, Anderson JJ, Skrinar GS, LePoole SR, Zerbini CF, DeLuca C, Jolesz F. Fibromyalgia Syndrome is not associated with abnormalities in muscle energy metabolism. Scand J. Rheum Suppl. 94:19, 1992. Selected for cash award at Second World Congress on Myofascial Pain, Fibromyalgia, August, 1992, Copenhagen, Denmark.

14. Mason JH, Silverman SL, Weaver AL, SIMMS RW. The impact of fibromyalgia on multiple aspects of health status. Scand J. Rheum 1992; Suppl. 94:33
15. Skrinar GS, SIMMS RW, Roy SH, Anderson JJ, Hrovat M, Zerbini CF. How do fibromyalgia patients rate levels of exertion? A comparative study with sedentary controls. Scand J. Rheum. 1992; Suppl. 94:30
16. SIMMS RW, Fortin P, Rochon P, Anderson JJ, Chalmers TC, Felson DT. The comparative toxicity of NSAIDS: results of a meta-analysis in OA and RA trials, 1987-1990. Arthritis Rheum 1992; 35: S219
17. Zerbini CAF, Anderson JJ, Kane KA, Ju ST, Campistol JM, SIMMS RW, Cohen AS, Skinner M. β -2 microglobulin level as a predictive marker of survival in AL amyloidosis. Arthritis Rheum 1992; 35:S130
18. SIMMS RW, Falk R, Skinner M, Cohen AS. Cardiac transplantation in AL amyloidosis: experience in three patients. Oral presentation at the 7th International Congress on Amyloidosis, Kingston, Ontario. July, 1993
19. Roy SH, SIMMS RW, LePoole SR, Anderson JJ, Hrovat M, Zerbini CAF, Skrinar GS, DeLuca CJ, Jolez F. Measurement of muscle fatigue in fibromyalgia syndrome by surface EMG. Arthritis Rheum 1992; 35: S161
20. Cohen AS, Skinner M, Jones LA, SIMMS RW, Lewis WD, Jenkins RL. First liver transplantation in USA for patient with familial amyloidotic polyneuropathy. J. Rheumatol 1993; 20: 184.
21. Rochon PA, Gurwits JH, Fortin PR, SIMMS RW, Minaker KL, Felson DT, Chalmers TC. Does association with a pharmaceutical manufacturer affect the results of NSAID trials? Clin Pharm Therap 1993; 53: 214
22. SIMMS RW, Prout M, Skinner M, Cohen AS. The epidemiology of AL amyloidosis: a preliminary study. Poster presentation at the 7th International Congress on Amyloidosis, Kingston, Ontario. July, 1993
23. Skinner M, Anderson JJ, Wang M, SIMMS RW, Falk R, Jones LA, Cohen AS. Treatment of patients with primary amyloidosis. Poster presentation at the 7th International Congress on Amyloidosis, Kingston, Ontario. July, 1993
24. Skinner M, Lewis WD, SIMMS RW, Jones LA, Cohen AS, Falk R, Jenkins R, Ju ST, Kane K, Kasirsky J. Liver transplantation in FAP: a report of 7 cases. Oral presentation at the 7th International Congress on Amyloidosis, Kingston, Ontario. July, 1993
25. SIMMS RW, Zerbini CAF, Anderson JJ, Felson DT. Treatment of glucocorticoid-induced osteoporosis: a meta-analysis. Arthritis Rheum 36: S50, 1993

26. Berg A, Chipkin S, Anderson JJ, Lee V, Skinner M, Cohen AS, SIMMS RW. Autonomic neuropathy in primary amyloidosis and its effect on survival. Arthritis Rheum 36: S162, 1993
27. Anderson J, Wang M, SIMMS RW, Skinner M. Melphalan/prednisone/ colchicine vs colchicine treatment in AL amyloidosis. Arthritis Rheum 36: S202, 1993
28. Scola C, Berg AM, SIMMS RW. Prolonged weakness after high dose corticosteroids and neuromuscular blockade. Arthritis Rheum 37: S243, 1994
29. Skinner M, Anderson JJ, SIMMS RW, Falk R, Libby C, Jones LA. Randomized trial of treatment for primary (AL) amyloidosis. Arthritis Rheum 37: S243, 1994
30. Comenzo RL, SIMMS RW, Sarnicki DL, Vosburgh E, Skinner M. Primary amyloidosis: feasibility of high-dose melphalan with mobilized blood stem-cell support. Blood 84: S706a, 1994
31. SIMMS RW, Hrovat M. Role of phosphodiesterases in the muscles of patients with fibromyalgia syndrome. Arthritis Rheum 38: S228, 1995
32. Comenzo RL, Falk RH, SIMMS RW, Vosburgh E, Skinner M. IV melphalan with blood stem cell rescue for AL amyloidosis: a two-year experience. Arthritis Rheum 39: S49, 1996
33. Amin S, LaValley MP, SIMMS RW, Felson DT. A meta-analysis evaluating the efficacy of calcium and vitamin D treatment for corticosteroid-induced osteoporosis. Arthritis Rheum 40: S123, 1997
34. Seibold JR, Korn J, SIMMS RW, Clements PJ, Moreland L, Mayes MD, Furst DE, Rothfield N, Steen V, Weisman M, DeMarco P, Collier D, Wigley F, Merkel PA, Csuka ME, Rocco S, Erikson M, Hannigan J, Harkonen WS, Sanders ME. Controlled trial of recombinant human relaxin in diffuse scleroderma. Arthritis Rheum 40: S136, 1997
35. Amin S, LaValley MP, Simms RW, Felson DT . A meta-analysis ranking drugs by efficacy for management of corticosteroid-induced osteoporosis.. Arthritis Rheum 41: S137, 1998 .
36. The use of intravenous epoprostenol for the treatment of pulmonary hypertension associated with scleroderma. Klings E, Simms RW, Jeong MH, Hill NS, Korn J, Farber HW. Arthritis Rheum 41: S239, 1998.
37. Merkel PA, Gelbard RB, Anderson JJ, Kaluta A, Kissin EY, Schwartz A, Simms RW, Falanga V, Korn JH. Reliability and utility of durometer measurements of skin hardness for scleroderma. Arthritis Rheum 46: S174, 2002

38. Simms RW, Farber H, Kissin G, York M, Korn JH. Intravenous epoprostenol for severe digital ischemia in scleroderma, *Arthritis Rheum* 48: S, 2004
39. Simms RW, Farber HW, Davidoff R, Korn JH. Correlation between echocardiographic estimate of pulmonary artery pressure and right heart catheterization in scleroderma. *Proceedings of XII th International Workshop on Scleroderma, Cambridge, UK 2004*
40. Lafyatis R, Kissin E, Viger K, Merkel PA, Simms RW. Rituximab treatment for patients with diffuse cutaneous sclerosis – A phase I study. *Arthritis Rheum* 54: S523, 2006
41. van Bon L, Popa C, Huijbens R, Vonk M, York M, SIMMS RW, Hesselstrand R, Wuttge DM, Lafyatis R, Radstake TRDJ. Distinct temporal evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis. Submitted (Federation of Clinical Immunology Societies), 2009
42. Radstake TRDJ, van Bon L, Broen J, Hussiani R, Hesselstrand R, Wuttge DM, Deng Y, SIMMS RW, Lubberts E, Lafyatis R. The pronounced Th17 profile in systemic sclerosis together with intracellular expression of TGF β and IFN γ distinguishes different SSc clinical phenotypes. Submitted (Federation of Clinical Immunology Societies), 2009
43. Radstake TRDJ, van Bon L, Broen J, Wenink M, Santegoets K, Deng Y, Hussaini A, SIMMS RW, Cruikshank W, Lafyatis R. Increased frequency and compromised function of T regulatory cells in systemic sclerosis is related to diminished CD69 and TGF β expression. Submitted (Federation of Clinical Immunology Societies), 2009

National/International Invited Lectures/Presentations

- 8/1/92 “Muscle Metabolism in Fibromyalgia, an NMR Spectroscopy Study”, Second International Conference on Myofascial Pain and Fibromyalgia, Copenhagen
- 3/19/93 “Fibromyalgia Syndrome: Current Controversies”, Rheumatology Grand Rounds, Cleveland Clinic Foundation, Cleveland, Ohio
- 5/19/93 “Muscle Studies in Fibromyalgia Syndrome”, Workshop on Fibromyalgia Syndrome, NIH/NIAMS, Bethesda, MD
- 6/11/94 “The Cost of Fibromyalgia Treatment: Comparison with Rheumatoid Arthritis and Osteoarthritis”, Physical Medicine Research Foundation, 7th International Symposium, Vancouver, Canada
- 6/13/94 “Measurement of Severity and Function in Fibromyalgia”, Physical Medicine Research Foundation, 7th International Symposium, Vancouver, Canada
- 10/21/94 “Controversies in Peripheral Mechanisms in Fibromyalgia”, Non-Articular Rheumatism Study Group, American College of Rheumatology Annual Meeting, Minneapolis, MN
- 3/29/95 “Rheumatic Manifestations of HIV Infection” and “Fibromyalgia Syndrome in 1995”, Visiting Professor Series, St. Margaret Memorial Hospital, Pittsburgh, PA
- 3/30/95 “Corticosteroid-induced Osteoporosis”, Rheumatology Grand Rounds, University of Pittsburgh, Pittsburgh, PA
- 5/8-12/95 “The Musculoskeletal Examination”, “Lyme Disease: What’s New?”, “Controversies in Rheumatoid Arthritis”, “Use and Abuse of Laboratory Tests in Rheumatic Disease”, Boston University School of Medicine, Department of Continuing Education, Hilton Head, SC
- 11/21/95 “Fibromyalgia Syndrome and Chronic Fatigue Syndrome”, Medical Grand Rounds, Del Ray Community Hospital, Del Ray Beach, FL
- 2/21/96 “The Natural History of Fibromyalgia Syndrome”, Province of Saskatchewan Disability Conference, Regina, Saskatchewan, Canada
- 7/15/96 “Steroid-induced Osteoporosis”, Wisconsin Rheumatism Association, Milwaukee, WI
- 7/16/96 “Guidelines for Treatment of Rheumatoid Arthritis: Who Needs Them?” Medical Grand Rounds, Columbia Hospital, Milwaukee, WI

- 3/3/97 “Treatment of Fibromyalgia”, Workshop on Difficult to Diagnose and Ill Defined Conditions, Institute of Medicine, National Academy of Sciences, Washington, DC
- 6/25/98 “Treatment of Fibromyalgia Syndrome”, Pan-American League Against Rheumatism (PANLAR), Montreal, Canada
- 5/25/99 “Fibromyalgia Syndrome”, Methodist Hospital, Indianapolis, IN
- 6/3/00 “Practice Guidelines for Rheumatoid Arthritis: Who Needs Them?”, Treatment of Rheumatic Diseases in 2000, a Regional Symposium, Dallas, TX
- 6/6/03 “New Perspectives in Scleroderma”, São Paulo Rheumatology Association, São Paulo, Brazil
- 6/6/03 “Recent Advances in Corticosteroid-induced Osteoporosis”, São Paulo Rheumatology Association, São Paulo, Brazil
- 6/23/05 “Rational Laboratory Testing in Rheumatic Disease”, Orear Institute Review Course in Internal Medicine, Kansas City, MO
- 6/23/05 “Current Management of Rheumatoid Arthritis”, Orear Institute Review Course in Internal Medicine, Kansas City, MO
- 8/21/06 “Recent Advances in Scleroderma”, Rocky Mountain Rheumatology Association, Denver, CO
- 8/22/06 “Cardiopulmonary Complications of Scleroderma”, Rheumatology Grand Rounds, University of Colorado, Denver, CO
- 10/6/06 “Recent Advances in Scleroderma”, Rheumatology Grand Rounds, University of Rochester School of Medicine and Dentistry, Rochester, NY
- 1/10/07 “Pathophysiology of Scleroderma, 2007”, Rheumatology Grand Rounds, Upstate Medical Center, SUNY, Syracuse, NY
- 1/11/07 “Recent Advances in Scleroderma”, Medical Grand Rounds, Upstate Medical Center, SUNY, Syracuse, NY
- 10/16/07 “Recent Advances in Scleroderma”, Rheumatology Rounds, Ohio State Medical Center, Columbus, OH
- 5/7/08 “Fibrotic Mechanisms in Scleroderma”, PANLAR/EUSTAR sponsored course: “Teaching the Teachers of Scleroderma in South America”, Campinas, Brazil

- 5/7/08 “The Immunology of Scleroderma”, PANLAR/EUSTAR sponsored course: “Teaching the Teachers of Scleroderma in South America”, Campinas, Brazil
- 11/12/08 “Blue, Swollen Fingers and Shortness of Breath: Scleroderma Evaluation and Management in 2008”, Chicago Rheumatism Society, Chicago, IL
- 1/9/09 “Update on Stem Cell Transplantation for Scleroderma, “Rheumatology Grand Rounds, Medical University of South Carolina, Charleston, SC
- 11/16/13 “Stem Cell Transplantation for Scleroderma”, Tristate Scleroderma Foundation Research Symposium, Hospital for Special Surgery, NY, NY
- 4/3/2015 “Pulmonary Hypertension in Connective Tissue Disease: 2015 and Beyond” Rheumatology Grand Rounds, West Penn Hospital, Pittsburgh, PA
- 7/18/2015 “Conditions Associated with Scleroderma,” Scleroderma Foundation National Conference, Nashville, TN
- 10/24/15 “Update on Therapy for Scleroderma” Scleroderma Foundation, Heartland Chapter Research Forum, Omaha, NB
- 08/06/16 “Update on Scleroderma Lung Disease” Rheumatology Grand Rounds, Stanford University, Stanford, CA
- 10/07/16 “Update on Scleroderma Lung Disease” Rheumatology Grand Rounds, University of Pittsburgh, Pittsburgh, PA

Local/Regional Invited Lectures/Presentations (selected)

- 5/7/93 “Fibromyalgia and Chronic Fatigue Syndromes: Current Concepts”, Medical Grand Rounds, Lahey Clinic, Burlington, MA
- 5/14/93 “Rheumatic Manifestations of HIV Infection”, Rheumatology Grand Rounds, Roger Williams General Hospital, Providence, RI
- 5/25/93 “Gastrointestinal Manifestations of Amyloidosis”, Gastroenterology Grand Rounds, Massachusetts General Hospital, Boston, MA
- 6/7/93 “Rheumatic Manifestations of HIV Infection”, Rheumatology Grand Rounds, Massachusetts General Hospital, Boston, MA
- 10/15/93 “Update on Systemic Amyloidosis”, Rheumatology Grand Rounds, Roger Williams General Hospital, Providence, RI

- 2/16/94 “Fibromyalgia”, Hoosic Serunian Primary Care Symposium, Medical Center of Central Massachusetts, Worcester, MA
- 5/16/94 “Fibromyalgia and Chronic Fatigue Syndromes: Current Concepts”, Chronic Pain in Women Symposium, Faulkner Hospital, Boston, MA
- 9/12/94 “Current Concepts in Fibromyalgia: 1994”, Harvard Medical School Postgraduate Rheumatology Course, Boston, MA
- 11/5/94 “Seronegative Spondyloarthropathies and the Foot”, The Boston Foot Course, Boston University School of Medicine, Department of Orthopedics, Boston, MA
- 11/18/94 “Fibromyalgia: Differentiation From Other Pain Conditions”, Nurse Practitioner National Primary Care Conference, Boston, MA
- 11/21/95 “Fibromyalgia Syndrome in 1995”, Rheumatology Grand Rounds, Brigham and Women’s Hospital, Boston, MA
- 1/17/96 “Steroid-induced Osteoporosis”, Rheumatology Grand Rounds, Tufts-New England Medical Center, Boston, MA
- 1/29/96 “Steroid-induced Osteoporosis”, Rheumatology Grand Rounds, Massachusetts General Hospital, Boston, MA
- 2/16/96 “Rheumatic Manifestations of HIV Infection”, Rheumatology Grand Rounds, Roger Williams Hospital, Providence, RI
- 9/27/96 “Guidelines for Treatment of Rheumatoid Arthritis: Who Needs Them?”, Medical Grand Rounds, St. Vincent’s Hospital, Worcester, MA
- 11/1/96 “The Origin of Pain in Chronic Pain Syndromes”, Gelb Symposium, Tufts University Dental School, Boston, MA
- 11/19/96 “Corticosteroid-induced Osteoporosis”, Endocrine Grand Rounds, Boston Medical Center, Boston, MA
- 4/20/97 “Meet the Professor”, ACR Regional Meeting, Boston, MA
- 5/19/97 “Practice Guidelines for Rheumatoid Arthritis: Who Needs Them?”, Rheumatology Grand Rounds, Massachusetts General Hospital, Boston, MA
- 6/24/97 “Corticosteroid-induced Osteoporosis”, Endocrine Grand Rounds, New England Medical Center, Boston, MA
- 1/12/98 “Update on Fibromyalgia Syndrome”, Rheumatology Grand Rounds, Massachusetts General Hospital, Boston, MA

6/5/98	“Fibromyalgia Syndrome”, Medical Grand Rounds, Jordan Hospital, Plymouth, MA
10/23/98	“Fibromyalgia Syndrome in 1998”, Rheumatology Grand Rounds, University of Massachusetts, Worcester, MA
5/25/99	“New Therapies for Rheumatoid Arthritis”, Medicine Grand Rounds, Roger Williams Hospital, Providence, RI
6/18/99	“New Arthritis Therapies”, Massachusetts Academy of Family Physicians Annual Meeting, Sturbridge, MA
12/15/99	“Fibromyalgia Syndrome in the New Millennium”, Medicine Grand Rounds, Sturdy Memorial Hospital, Stoughton, MA
1/13/00	“Fibromyalgia Syndrome in the New Millennium”, Rheumatology Grand Rounds, Tufts New England Medical Center, Boston, MA
4/13/00	“New Therapies for Rheumatoid Arthritis and Osteoarthritis”, Primary Care Conference, Brockton VA Hospital, Brockton, MA
4/27/00	“New Therapies for Rheumatoid Arthritis and Osteoarthritis”, Primary Care Conference, Boston VA Hospital, Boston, MA
6/20/00	“Glucocorticoid-induced Osteoporosis”, Arthritis Grand Rounds, Massachusetts General Hospital, Boston, MA
3/18/02	“Osteoarthritis”, Primary Care Grand Rounds, St. Elizabeth’s Hospital, Boston, MA
4/12/02	“Current Controversies in Fibromyalgia Syndrome”, The Gynecologist As Primary Care Provider, BU CME Course, Cambridge, MA
9/23/02	“Osteoarthritis: Diagnosis and Management”, Housestaff Conference, St. Elizabeth’s Hospital, Boston, MA
3/31/03	“Rheumatoid Arthritis: Current Concepts”, Housestaff Conference, St. Elizabeth’s Hospital, Boston, MA
2/19/04	“Recent Advances in Scleroderma”, Medical Grand Rounds, Faulkner Hospital, Boston, MA
4/21/05	“Recent Advances in Scleroderma”, Rheumatology Grand Rounds, New England Medical Center, Boston, MA

10/27/05	“Unlocking the Mysteries of SLE”, Lupus Foundation, Kingston, MA
10/28/05	“What’s New in Scleroderma”, Rheumatology Grand Rounds, University of Massachusetts Medical Center, Worcester, MA
11/19/05	“Recent Therapeutic Advances in Scleroderma and What’s on the Horizon”, Scleroderma Foundation, Tri-State Chapter, Mt. Sinai Medical Center, NY
11/30/05	“Recent Therapeutic Advances in Scleroderma and What’s on the Horizon”, Hematology/Oncology Grand Rounds, Massachusetts General Hospital, Boston, MA
3/29/06	“Recent Therapeutic Advances in Scleroderma and What’s on the Horizon”, Medical Grand Rounds, Carney Hospital, Boston, MA
6/2/06	“Recent Therapeutic Advances in Scleroderma and What’s on the Horizon”, Medical Grand Rounds, North Shore Medical Center, Salem, MA
6/7/06	“Update on the Cardiopulmonary Complications of Scleroderma”, Rheumatology Grand Rounds, Yale University School of Medicine, New Haven, CT
6/21/06	“Recent Therapeutic Advances in Scleroderma and What’s on the Horizon”
9/6/06	“Use and Abuse of Laboratory Studies in Rheumatology”, BUSM Core Curriculum in Primary Care, Dedham, MA
9/12/06	“Update in Scleroderma”, Medical Grand Rounds, Newton Wellesley Hospital, Newton, MA
2/09/08	“Running Injuries”, BUSM Core Curriculum in Primary Care, Dedham, MA
5/29/08	“Mechanisms of Fibrosis”, Rheumatology Grand Rounds, Tufts Medical Center, Boston, MA
10/18/08	“Rheumatoid Arthritis: Management in 2008”, BUSM Core Curriculum in Primary Care, Dedham, MA
2/24/10	“Scleroderma: Bench to Bedside in 2010,” Medicine Grand Rounds, St. Elizabeth’s Medical Center, Boston, MA
9/12/10	“Mimics of Scleroderma,” Harvard Rheumatology Review Course, Boston, MA
10/08/10	“Appropriate Use of Laboratory and Imaging Studies”, BUSM Core Curriculum in Primary Care, Dedham, MA

- 3/29/11 “Scleroderma: Bench to Bedside in 2011,” Rheumatology Grand Rounds, Massachusetts General Hospital, Boston, MA
- 5/21/11 “Endothelin-1 Blockade in Sclerosing Disorders”, 5th Annual Symposium on Nephrogenic Systemic Fibrosis and Allied Systemic Fibrosing Disorders, Yale University School of Medicine, New Haven, CT
- 6/14/11 “Scleroderma: Bench to Bedside in 2011,” Rheumatology Grand Rounds, Dartmouth Medical School, Hanover, NH
- 9/5/12 “Scleroderma: Bench to Bedside in 2012,” Inaugural Mary Lou Gilbane-Carolan lectureship in Scleroderma, Warren Alpert School of Medicine, Brown University
- 9/5/12 “A New Methodology for Expediting Novel Therapies in Scleroderma” Rheumatology Grand Rounds, Warren Alpert School of Medicine, Brown University
- 10/4/2013 “Anti-Type I Interferon alpha receptor antibody in Scleroderma: A Phase I Trial” Rheumatology Grand Rounds, Beth Israel Deaconess Medical Center, Boston, MA
- 10/11/2013 “Anti-Type I Interferon alpha receptor antibody in Scleroderma: A Phase I Trial” Rheumatology Grand Rounds, University of Massachusetts Medical Center, Worcester, MA
- 1/21/2014 “Anti-Type I Interferon alpha receptor antibody in Scleroderma: A Phase I Trial” Rheumatology Grand Rounds, Massachusetts General Hospital, Boston, MA
- 3/18/2014 “Anti-Type I Interferon alpha receptor antibody in Scleroderma: A Phase I Trial” Rheumatology Grand Rounds, Brigham and Women’s Hospital, Boston, MA
- 12/15/2015 “Scleroderma: Bench to Bedside in 2016” Medicine Grand Rounds, MetroWest Medical Center, Framingham, MA
- 12/9/2016 “CTD-Associated PAH: A Case for Discussion” Tufts NEMC Pulmonary Hypertension Course, Cambridge, MA
- 04/30/2017 “Pulmonary Disease in Scleroderma” Rheumatology Grand Rounds, Tufts New England Medical Center, Boston, MA
- 2/09/2018 “Scleroderma: Bench to Bedside in 2018” Medicine Grand Rounds, North Shore Medical Center, Salem, MA
- 2/28/2018 “Update on Pulmonary Disease in Scleroderma” Pulmonary Grand Rounds, BU Medical Center, Boston, MA

- 4/6/2018 “Canabinoids in Scleroderma: Biologic rationale and Clinical Trial Update”
Patient Research Symposium, Scleroderma Foundation, New England Chapter,
Peabody, MA
- 9/23/18 “Systemic Sclerosis” Advances in Rheumatology-Harvard Review Course, John
Stone, MD, Course Director, Boston, MA
- 12/7/2018 “Challenging Cases in CTD-PAH” Simms RW, Farber HF. 16th Annual Update in
Pulmonary Hypertension, Nicholas Hill, MD, Course Director, Tufts Medical
Center and Postgraduate Institute for Medicine
- 4/2/2019 “Advances in Treatment of Scleroderma” Rheumatology Grand Rounds, Brigham
and Women’s Hospital, Boston, MA
- 2/20/2020 “Advances in Treatment of Scleroderma” Rheumatology Grand Rounds, Tufts
Medical Center, Boston, MA
- 3/9/2020 “Advances in Treatment of Scleroderma” Medical Grand Rounds, Dartmouth
Hitchcock Medical Center, Lebanon, NH
- 12/2/2020 “Scleroderma Mimics” Rheumatology Grand Rounds, Boston University School
of Medicine, Boston, MA

Intramural Invited Lectures (selected)

- 7/21/99 “New Therapies for RA”, Section of General Internal Medicine
- 6/16/00 “New Arthritis Therapies”, Harrison Pavilion, NP Conference
- 9/11/02 “Osteoarthritis: Recognition and Management” Evans Conference
- 2/6/04 “Recent Advances in Rheumatology: Therapy of Ankylosing Spondylitis”,
Medical Grand Rounds, Boston Medical Center, Boston, MA
- 3/01/04 “Therapy of Autoimmune Disease”, Ophthalmology Grand Rounds, Boston
Medical Center, Boston, MA
- 9/07/05 “The Scleroderma Lung Study: Preliminary Results”, Rheumatology Grand
Rounds, Boston Medical Center, Boston, MA
- 3/10/06 “What’s New in Rheumatology, 2006”, Medical Grand Rounds, Boston Medical
Center, Boston, MA

9/5/07	“Recent Advances in Scleroderma”, Rheumatology Grand Rounds, Boston Medical Center, Boston, MA
1/04/08	“Blue, Swollen Fingers and Shortness of Breath: Scleroderma, Evaluation and Management in 2008”, Medical Grand Rounds, Boston Medical Center, Boston, MA
9/3/08	“Fibrotic Mechanisms in Scleroderma”, Rheumatology Grand Rounds, Boston Medical Center, Boston, MA
1/16/09	“A 55 Year Old Woman with Weakness and Shortness of Breath”, Medical Grand Rounds, Boston Medical Center, Boston, MA
9/2/2009	“Mimics of Scleroderma, “ Rheumatology Grand Rounds, Boston Medical Center, Boston, MA
4/27/2010	“Fibrotic Mechanisms in Scleroderma”, Molecular and Cell Biology Seminar, Boston University School of Medicine, Boston, MA
2/8/2012	“The Role of Endothelin-1 in Scleroderma: Opportunities for Intervention” Rheumatology Grand Rounds, Boston Medical Center, Boston, MA
09/04/2013	“Anti-Type I Interferon alpha receptor antibody in Scleroderma: A Phase I Trial” Rheumatology Grand Rounds, Boston Medical Center, Boston, MA
4/31/17	“Scleroderma: Bedside to Bench and Back in 2017” Medical Grand Rounds, Boston Medical Center, Boston, MA
2/28/18	“Pulmonary Complications of Scleroderma: An Update” Pulmonary Grand Rounds, Boston Medical Center, Boston, MA
11/3/20	“Scleroderma Mimics”, Fellow’s Conference, Rheumatology Section, Dartmouth Hitchcock Medical Center, Lebanon, NH

Principal Investigator Grant Support

DOD	Exosome-Mediated Regulation of Macrophage Activation Across Molecular Subsets in Systemic Sclerosis (P Pioli, Co-PI) submitted 9/9/20
NIH/NIAMS	A Randomized, Open-Label, Phase II/II Multi-Center Study of High-dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATAGAM and Autologous Transplantation with Auto-CD34+ HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis 9/2005-9/2014 Total Award to Section: \$801,413
Actelion	A Two Stage Prospective observational cohort study in Scleroderma Patients to Evaluate Screening Tests and the Incidence of Pulmonary Arterial Hypertension 2/1/09-2/28/14 Total Award to Section: \$350,000
Actelion	DUAL: A Double Blind Placebo Controlled Trial of Macitentan in Ischemic Digital Ulcers in Scleroderma 4/1/12-3/30/13 Total Award to Section: \$83,000
InterMune	The LOTUSS Trial: An Open Label, Randomized, Phase 2 Study of the Safety and Tolerability of Pirfenidone when Administered to Patients with Systemic Sclerosis-Related Lung Disease. 6/1/13-3/31/14 Total Award to Section: \$105,000
NIH/NIAMS	Muscle Metabolism in Fibromyalgia Syndrome 7/1/89-3/30/92 Total Award: \$137,500
Connetics Corp.	Open Label Study of Safety of Subcutaneous Continuous Infusion of Recombinant Human Relaxin 3/13/98-10/13/98 Total Award: \$13,200
ACR/Searle	ACR CME Initiative for Primary Care Physicians 3/99-12/99 Total Award: \$40,000
Connetics Corp.	Open Label Study of Safety of Subcutaneous Continuous Infusion of Recombinant Human Relaxin II 3/00 Total Award: \$66,000

Otsuka Research	A Multicenter, Blinded, Randomized, Placebo-controlled, Sequential Crossover Study of OPC-28326 in Subjects with Raynaud's Phenomenon 12/01-9/02 Total Award: \$15,000
Novartis	A Randomized, Double-blinded, Placebo Controlled, Multiple-Dose, Multi-Center Pilot Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Doses of QAX576 in Patients with Pulmonary Fibrosis Secondary to Systemic Sclerosis 1/2008-1/20010 Total Award to Section: \$190,000
ACR	Fellowship Program Award 7/1/08-6/30/09 Total Award to Section: \$25,000
United Therapeutics	An Evaluation of the Pharmacokinetics and Safety of Fixed and Escalating Doses of Oral Treprostinil Diethanolamine 2/1/09-6/1/11 Total Award to Section: \$155,477
United Therapeutics	Digital Ischemic Lesions in Scleroderma treated with Oral Treprostinil Diethanolamine: A Randomized, Double-Blind, Placebo Controlled Trial 5/1/09-4/30/11 Total Award to Section: \$76,220
United Therapeutics	DISTOL extension: Digital Ischemic Lesions in Scleroderma treated with Oral Treprostinil Diethanolamine: an Open Label Multicenter Extension Trial 8/1/09-8/31/11 Total Award to Section: \$75,520
MedImmune	A Phase I, Multicenter, Open label Study to Evaluate the Safety and Tolerability of Single and Multiple Intravenous Doses of Medi-546, an Anti-Type 1 Interferon Monoclonal Antibody 8/1/09-7/31/11 Total Award to Section: \$69,754

Co-Investigator Grant Support

NIH/NIAMS	Pathogenesis of Scleroderma (R Lafyatis, PI), Clinical Core PI 1P50AR060780-01 9/1/11-8/30/16 Total Award to Section: \$8,000,000
Genzyme	An Open Label Trial of Anti-TGF β , Fresolimumab, in Systemic Sclerosis- A Phase One Biomarker Trial (R Lafyatis, PI) 6/1/12-5/30/13 Total Award to Section: TBD

Hoffman-La Roche	A Phase II/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab versus Placebo in patients with Systemic Sclerosis (R Lafyatis, PI) 6/1/12-5/30/13 Total Award to Section: 80,000
Regeneron	A Randomized, Double-Blind, Placebo-Controlled Trial of IL1-Trap, Rilonacept, in Systemic Sclerosis-A Phase I/II Biomarker Trial 6/1/12-5/30/13 Total Award to Section: \$60,000
Therakos, Inc.	Photopheresis in the Treatment of Rheumatoid Arthritis 9/26-6/4/92 Total Award to Section: \$35,000
Pfizer, Inc.	Double Blind Study of Two Dose Ranges of Tenidap Sodium in the Treatment of Osteoarthritis 5/1/91-4/30/92 Total Award to Section: \$15,000
Therakos, Inc.	A Phase III Randomized, Multi-center Clinical Trial of Photopheresis in the Treatment of Systemic Sclerosis 3/22/93-4/22/94 Total Award to Section: \$15,600
Berlex Labs	Oral Iloprost for the Treatment of Raynaud's Phenomenon Secondary to Systemic Sclerosis 12/22/95-6/1/96 Total Award to Section: \$120,000
Connective Therapeutics	A Phase II Study of the Safety and Efficacy of Subcutaneous Continuous Infusion of Recombinant Human Relaxin for 24 Weeks in Patients with Systemic Sclerosis with Diffuse Scleroderma 6/1/96-3/1/99 Total Award to Section: \$90,000
Genetics Institute	A Phase 1/2 Randomized, Double-Masked, Placebo-Controlled Study of rhIL-11 in the Treatment of Subjects with Active Rheumatoid Arthritis 9/1/97-3/1/99 Total Award to Section: \$40,000
Connetics Corp.	A Phase II/III Placebo-Controlled Safety and Efficacy Study of Recombinant Human Relaxin Therapy in Subjects with Systemic Sclerosis with Diffuse Scleroderma 6/1/99-6/1/01 Total Award to Section: \$165,880
NIH/NHBLI	Oral Cyclophosphamide versus Oral Placebo in Systemic Sclerosis Pulmonary Alveolitis 9/1/99-7/30/04 Total Award to Section: \$148,000
Biogen Idec	A Phase I Open Label Trial of Interferon Beta-1a in the Treatment of Systemic Sclerosis 2/1/01-3/1/06 Total Award to Section: \$30,000

Genentech	Rituximab Treatment of Scleroderma, An Open Label, Phase I Study 3/31/04-6/1/06 Total Award to Section: \$50,000
Mediquest	A Phase III “In Life” Study of a Topical Gel Formulation of Nitroglycerin MQX-503 and Matching Placebo Gel in the Prevention of Raynaud’s Phenomenon 11/30/05-9/27/06 Total Award to Section: \$25,000
Mediquest	Phase III Open Label Study of a Topical Gel Formulation of Nitroglycerin MQX-503 in the Treatment and Prevention of Raynaud’s Phenomenon 8/24/06 Total Award to Section: \$67, 000
Encysive	A Long-Term Open Label Study to Evaluate the Safety of Sitaxsentan Sodium in Patients with Pulmonary Arterial Hypertension 6/23/04-1/1/05 Total Award to Section: \$20,000
NIH	A Multicenter, Parallel, Randomized, Controlled, One-Year Study of Bovine Collagen Type I Versus Placebo in Systemic Sclerosis of Less Than or Equal to Ten Years Duration 12/1/99-11/1/05 Total Award to Section: \$33,000
Actelion	A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Effect of Bosentan on Healing and Prevention of Ischemic Digital Ulcers in Patients with Systemic Sclerosis 10/1/03-9/22/05 Total Award to Section: \$48,000
Actelion	BUILD 2: A Double Blind, Randomized, Placebo Controlled Multicenter Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Interstitial Lung Disease Associated with Scleroderma 8/1/03-3/1/06 Total Award to Section: \$58,000
Actelion	BUILD 2-OL: Bosentan Use in Interstitial Lung Disease (Open Label) Long Term Open Label Study in Patients with Interstitial Lung Disease Associated with Systemic Sclerosis Who Completed BUILD 2 8/2/04-5/1/06 Total Award to Section: \$22,000
Actelion	Effects of Combination Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients with Pulmonary Arterial Hypertension – A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Prospective, Event Driven Phase IV Study (COMPASS) 9/06- 10/09 Total Award to Section: 180,000

